'One Shot and You're Thin': China's Weight-Loss Boom Meets Semaglutide's Side Effects
A rundown of semaglutide's five major side effects became one of Weibo's most-read health posts this week. Behind it sits a bigger story: a weight-loss drug boom racing ahead of its prescription regime, sold online with the slogan 'no dieting, no exercise, one shot and you're thin.'
A post walking through the five major side effects of semaglutide — nausea, vomiting, diarrhea, constipation, bloating, indigestion, reflux, most of them gastrointestinal and mostly in the first weeks of treatment — became one of Weibo's most-read health items on September 9. That a drug's fine print could out-trend the day's entertainment news says something about how many people are now taking, or considering, China's favorite weight-loss injection.
Semaglutide, the active ingredient in Ozempic and Wegovy, belongs to the GLP-1 class of drugs, developed for type 2 diabetes and famous for what they do to appetite and weight. China's regulator approved injectable semaglutide for weight management in June 2024, and the market has been running hot ever since: tirzepatide and the domestically developed mazdutide have joined it, and e-commerce platforms list "weight-loss pens" in abundance, from a few hundred to over a thousand yuan, with purchase flows that reporters found conspicuously simple for prescription medicines.
The slogan attached to the boom — "no dieting, no exercise, one shot and you're thin" (不节食不运动，一针就能瘦) — is exactly what doctors have begun campaigning against. Ying Huimin, who runs the fatty-liver and obesity clinic at Hangzhou Xixi Hospital, told Qianjiang Video that the drugs work by slowing gastric emptying and dampening appetite, which is also why users who eat little and move less tend to shed water and muscle rather than fat, and end up, in the phrase running through the comment threads, "thinner but flabbier." Her counterpart warnings, amplified by the trend: don't buy it as a cosmetic, don't share pens, and treat low blood sugar, persistent vomiting or stomach pain as reasons to see a doctor, not push through.
The frustration in the medical posts is aimed less at the drug than at the marketing around it. "People have heard it melts weight, and selectively ignore the pile of risks," one post complained, describing users who buy the drug privately and inject it "like a beauty shot" (美容针) — the same casual channeling of prescription medicine that has made weight-loss jab rumors a recurring celebrity story here; one comedian answered her own denial with math last month. Even the side-effect explainers carry a disclaimer now standard in Chinese health posts: content for reference only, see a doctor offline if unwell.
None of this has dented demand; China has well over a hundred million people with obesity and a health system where clinics for it are scarce outside big cities, so the appetite for a needle that seems to replace dieting is structural. The question the side-effect list poses is quieter: whether a prescription regime, designed around a doctor's review, can hold its shape inside an e-commerce checkout flow.